January 25 - 27, 2010, The Ritz Carlton, Philadelphia, PA
Register by Dec 04, 2009 and receive up to $698 off!
Download the Brochure
Chris Thomson PhD, Director of Licensing & Business Development at Astellas Pharma Europe Ltd on The Changing Fortunes of Antibacterial Drug Development and Commercialization
Sustained Release of Nitric Oxide from the Hybrid Nanoparticle Platform: A Novel Therapeutic Strategy for Cutaneous Infections with Dr. Adam Friedman
Visit the Download Center to check Speaker Submissions and past Attendees
Become a Pharma IQ Member and receive our weekly newsletter!
Learn more about sponsor & exhibit opportunities
Mark Your Calendar
Tell a Colleague
The global anti-infective market is currently estimated at $66.5 billion, with anti-bacterial agents accounting for more than 50% of sales. Many biotechs and pharmaceutical companies are seeing developments in later stage clinical trials, specifically in anti-bacterial and anti-fungal, both of which are growing in demand. The threat of bacterial resistant strains of infectious diseases continually increases and creates a race to develop an effective resistant drug to combat these strains.
The Anti-Infectives Summit will discuss effective lead generation approaches currently being used in anti-bacterial, anti-viral and anti-fungal drug discovery and address which biologics may play a role in anti-infective therapy.
Download a snapshot of our past attending companies
VPs, Heads, Directors and Managers of:
[ Register Now ]
Questions about IQPC's Conferences, Events or Training Seminars? Contact us on 1-800-882-8684 or email email@example.com now!